Oregon Health and Science University: Parkinson Disease trials

The registry lists 36 Parkinson Disease studies with Oregon Health and Science University as lead sponsor. 4 are open to participants now and 9 have results posted.

Early Phase 1 1Phase 1 2Phase 2 5Phase 4 3No phase 25(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• TURN-IT FOG: Improving Turning and Freezing of Gait in People With PDRecruitingNCT06815302Not applicable
• Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's DiseaseRecruitingNCT06772220Not applicable
• Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and CueingRecruitingNCT05818189Not applicable
• Balance Tele-Rehab in Parkinson's DiseaseRecruitingNCT05680597Not applicable
• Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's DiseaseCompletedNCT04387773Phase 4Results posted
• Video Based Mindfulness Based Stress ReductionCompletedNCT02705586Not applicableResults posted
• Effects of Cholinergic Augmentation on Measures of Balance and GaitCompletedNCT02206620Phase 2Results posted
• Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless StereotaxisCompletedNCT01703598Not applicableResults posted
• The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseCompletedNCT01521117Phase 4Results posted
• High and Low Dose Carbidopa Treatment of Parkinson's DiseaseCompletedNCT01399905Phase 2Results posted
• Cognitive Decline in Non-demented PDCompletedNCT01340885Phase 4Results posted
• Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's DiseaseCompletedNCT00912808Not applicableResults posted
• Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's DiseaseTerminatedNCT00794313Not applicableResults posted
• Mobility in Daily Life and Falls in Parkinson's Disease: Potential for RehabilitationActive, not recruitingNCT04897256Not applicable
• Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation ToolkitCompletedNCT04468919Not applicable
• Mobility Rehab, a Therapist-assisted System for Gait RehabilitationStatus unknownNCT03869879Not applicable
• Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)TerminatedNCT03716258
• Improving Walking Automaticity in Parkinson's Disease: Levodopa or DonepezilCompletedNCT03599726Early Phase 1
• Clinical Characteristics of Parkinson's Disease Subjects With Severe Hypertension During Motor OFFs.SuspendedNCT03433950
• Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's DiseaseStatus unknownNCT03288909
• Measuring Cortisol Levels in Persons With Parkinson's (PD)CompletedNCT02727270
• Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaTerminatedNCT02589340Phase 1
• Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation ImpactCompletedNCT02236286Not applicable
• Exercise, Brain Imaging, Cognition, and Gait in ParkinsonismCompletedNCT02231073Not applicable
• Postural Instability in Progressive Supranuclear PalsyCompletedNCT01563276
• COPE-Co-morbidities, Parkinson's Disease and ExerciseCompletedNCT01361724Not applicable
• Development of an Instrumented System to Measure Mobility in Parkinson's DiseaseCompletedNCT01174758
• Natural History of Levodopa-Induced Dyskinesia (LID)WithdrawnNCT01003002
• The Effects of Treadmill Versus Agility Training in Parkinson's DiseaseCompletedNCT00982709Not applicable
• Prospective Evaluation of Forceplate Measured Levodopa-Induced DyskinesiaCompletedNCT00912977
• Cognitive Behavioral Therapy for Depression in Parkinson's DiseaseTerminatedNCT00810628Not applicable
• Comparison of Continuous and Pulsatile Apomorphine in Parkinson's DiseaseWithdrawnNCT00758368Phase 2
• Expectation and Response to Levodopa and Acupuncture in Parkinson's DiseaseCompletedNCT00692328Not applicable
• Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's DiseaseCompletedNCT00666653Phase 1
• Low Dose Apomorphine and ParkinsonismWithdrawnNCT00472355Phase 2
• Methylphenidate and Parkinson's DiseaseCompletedNCT00359723Phase 2